Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
Chiu PK, Leow JJ, Chiang CH, Mok A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Teoh JY, Chu PS, Zhu G, Ye DW, Wu HC, Tan TW, Tsu JH, Ng CF, Chiong E, Huang CY. Chiu PK, et al. Among authors: zhang k. J Urol. 2023 Jul;210(1):88-98. doi: 10.1097/JU.0000000000003450. Epub 2023 Apr 10. J Urol. 2023. PMID: 37036248
A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
de la Rosette J, Dominguez-Escrig J, Zhang K, Teoh J, Barret E, Ramon-Borja JC, Muir G, Bohr J, de Reijke T, Ng CF, Leung CH, Sanchez-Salas R, Laguna P. de la Rosette J, et al. Among authors: zhang k. J Urol. 2023 Feb;209(2):347-353. doi: 10.1097/JU.0000000000003051. Epub 2022 Nov 28. J Urol. 2023. PMID: 36441776 Clinical Trial.
Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
Zhang K, Teoh J, Laguna P, Dominguez-Escrig J, Barret E, Ramon-Borja JC, Muir G, Bohr J, de Reijke TM, Pelechano Gómez P, Ng CF, Sanchez-Salas R, de la Rosette J. Zhang K, et al. JAMA Surg. 2023 Apr 1;158(4):343-349. doi: 10.1001/jamasurg.2022.7516. JAMA Surg. 2023. PMID: 36723911 Free PMC article.
Reply by Authors.
Chiu PK, Leow JJ, Chiang CH, Mok A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Teoh JY, Chu PS, Zhu G, Ye DW, Wu HC, Tan TW, Tsu JH, Ng CF, Chiong E, Huang CY. Chiu PK, et al. Among authors: zhang k. J Urol. 2023 Jul;210(1):98. doi: 10.1097/JU.0000000000003450.02. Epub 2023 May 4. J Urol. 2023. PMID: 37139611 No abstract available.
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs).
Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, Chiu PK, Campi R, Resta GR, Dibilio E, Pirola GM, Chiacchio G, Fuligni D, Brocca C, Giulioni C, De Stefano V, Serni S, Gauhar V, Ng CF, Gacci M, Teoh JYC. Nicoletti R, et al. Among authors: zhang k. Prostate Cancer Prostatic Dis. 2023 Jul 25. doi: 10.1038/s41391-023-00698-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37491432 Review.
26,022 results
You have reached the last available page of results. Please see the User Guide for more information.